Cognition Therapeutics (CGTX) was notified by Nasdaq that the company has regained compliance with the exchange’s continued listing standard for minimum share price under Rule 5550.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics Reports Q2 2025 Financial Results
- Cognition Therapeutics confirms aligment with FDA on path for zervimesine
- Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics
- Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)
- Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors